Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Targeting androgen receptor degradation with PROTACs from bench to bedside
Xiaojuan Jia, Xin Han
Biomedicine & Pharmacotherapy (2022) Vol. 158, pp. 114112-114112
Open Access | Times Cited: 35

Showing 1-25 of 35 citing articles:

Insight into Recent Advances in Degrading Androgen Receptor for Castration-Resistant Prostate Cancer
Qiao‐Hong Chen, Erick Munoz, Dennis Ashong
Cancers (2024) Vol. 16, Iss. 3, pp. 663-663
Open Access | Times Cited: 16
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Hydrophobic tag-based protein degradation: Development, opportunity and challenge
Qindi He, Xiaofei Zhao, Donglin Wu, et al.
European Journal of Medicinal Chemistry (2023) Vol. 260, pp. 115741-115741
Closed Access | Times Cited: 25
Transcriptional co-activators: emerging roles in signaling pathways and potential therapeutic targets for diseases
Priyanka Dey Talukdar, Urmi Chatterji
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 24
Application and challenges of nitrogen heterocycles in PROTAC linker
Yang Li, Junfeng Qu, Lizhi Jiang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 273, pp. 116520-116520
Closed Access | Times Cited: 13
PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
Yulu Zhang, Annan Ming, Junyan Wang, et al.
Pharmacological Research (2024) Vol. 205, pp. 107234-107234
Open Access | Times Cited: 8
Finding a needle in the haystack: ADME and pharmacokinetics/pharmacodynamics characterization and optimization toward orally available bifunctional protein degraders
Giulia Apprato, Giulia Caron, Gauri Deshmukh, et al.
Expert Opinion on Drug Discovery (2025)
Closed Access | Times Cited: 1
Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects
Megan Bonsor, Orchid Ammar, Sigrid Schnoegl, et al.
PROTEOMICS (2024) Vol. 24, Iss. 12-13
Open Access | Times Cited: 6
Target protein degradation by protacs: A budding cancer treatment strategy
Diksha Choudhary, Amritpal Kaur, Pargat Singh, et al.
Pharmacology & Therapeutics (2023) Vol. 250, pp. 108525-108525
Closed Access | Times Cited: 12
Targeted Degradation of Androgen Receptor by VNPP433-3β in Castration-Resistant Prostate Cancer Cells Implicates Interaction with E3 Ligase MDM2 Resulting in Ubiquitin-Proteasomal Degradation
Elizabeth Thomas, Retheesh S. Thankan, Puranik Purushottamachar, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1198-1198
Open Access | Times Cited: 11
Molecular properties, including chameleonicity, as essential tools for designing the next generation of oral beyond rule of five drugs
Giulia Caron, Diego García Jiménez, Maura Vallaro, et al.
ADMET & DMPK (2024)
Open Access | Times Cited: 4
A patent review of von Hippel-Lindau (vhl)-recruiting chemical matter: E3 ligase ligands for PROTACs and targeted protein degradation (2019-present)
Aina Urbina, Alex J. Hallatt, Jack Robertson, et al.
Expert Opinion on Therapeutic Patents (2025), pp. 1-42
Closed Access
Discovery of N-(1,2,4-Thiadiazol-5-yl)benzo[b]oxepine-4-carboxamide Derivatives as Novel Antiresistance Androgen Receptor Antagonists
Jianing Liao, Jinbiao Liao, Ying Wang, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Non-enzymatic protein targeting agents as a promising strategy for cancer treatment
M. Ambrose, Jin-Hyung Lee, Aleem Syed, et al.
Frontiers in Drug Discovery (2025) Vol. 5
Open Access
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Can Zhou, Shiwei Yang, Jun Wang, et al.
Bioorganic Chemistry (2025), pp. 108437-108437
Closed Access
Phase 1 study of HP518, a PROTAC AR degrader in patients with mCRPC: results on safety, pharmacokinetics, and anti-tumor activity
Arun Azad, Howard Gurney, Craig Underhill, et al.
Investigational New Drugs (2025)
Closed Access
A small molecule targeting the interaction between human papillomavirus E7 oncoprotein and cellular phosphatase PTPN14 exerts antitumoral activity in cervical cancer cells
Chiara Bertagnin, Lorenzo Messa, Matteo Pavan, et al.
Cancer Letters (2023) Vol. 571, pp. 216331-216331
Open Access | Times Cited: 9
Optimization of Potent Ligands for the E3 Ligase DCAF15 and Evaluation of Their Use in Heterobifunctional Degraders
Simon C. C. Lucas, Afshan Ahmed, Saba Ashraf, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 7, pp. 5538-5566
Closed Access | Times Cited: 3
UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer
Soohyun Lee, Hwa‐Ryeon Kim, Yaejin Woo, et al.
Advanced Science (2024) Vol. 11, Iss. 33
Open Access | Times Cited: 3
Molecular basis and dual ligand regulation of tetrameric estrogen receptor α/14-3-3ζ protein complex
B. Somsen, Eline Sijbesma, S. Leysen, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 7, pp. 104855-104855
Open Access | Times Cited: 8
Development of PROTACS degrading KRAS and SOS1
Gerhard Hamilton, Marie-Therese Eggerstorfer, Sandra Stickler
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics (2024) Vol. 32, Iss. 8, pp. 1257-1264
Open Access | Times Cited: 2
Advances in the understanding of androgen receptor structure and function and in the development of next-generation AR-targeted therapeutics
Wendy Effah, Marjana Khalil, Dong‐Jin Hwang, et al.
Steroids (2024) Vol. 210, pp. 109486-109486
Closed Access | Times Cited: 2
Let’s Go 3D! New Generation of Models for Evaluating Drug Response and Resistance in Prostate Cancer
Tina Petrić, Maja Sabol
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5293-5293
Open Access | Times Cited: 5
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Pengyun Li, Bingkun Li, Ning Yang, et al.
Expert Opinion on Therapeutic Patents (2023) Vol. 33, Iss. 7-8, pp. 477-492
Closed Access | Times Cited: 5
Dihydrotestosterone-based A-ring-fused pyridines: Microwave-assisted synthesis and biological evaluation in prostate cancer cells compared to structurally related quinolines
Márton A. Kiss, Miroslav Peřina, Laura Bereczki, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2023) Vol. 231, pp. 106315-106315
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top